These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 32447209)

  • 1. Design of integrin α
    Lv X; Zhang C; Shuaizhen Q; Yu R; Zheng Y
    Biomed Pharmacother; 2020 Aug; 128():110236. PubMed ID: 32447209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel dual-cyclic RGD peptides for α
    Liu J; Cheng X; Tian X; Guan D; Ao J; Wu Z; Huang W; Le Z
    Bioorg Med Chem Lett; 2019 Apr; 29(7):896-900. PubMed ID: 30732943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligands for mapping alphavbeta3-integrin expression in vivo.
    Schottelius M; Laufer B; Kessler H; Wester HJ
    Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide.
    Zhang Q; Lu L; Zhang L; Shi K; Cun X; Yang Y; Liu Y; Gao H; He Q
    Sci Rep; 2016 Feb; 6():19800. PubMed ID: 26842655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined integrin α
    Qi N; Zhang S; Zhou X; Duan W; Gao D; Feng J; Li A
    J Nanobiotechnology; 2021 Dec; 19(1):446. PubMed ID: 34949198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designed synthetic analogs of the α-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin αvβ3 homing domain.
    Diao Y; Han W; Zhao H; Zhu S; Liu X; Feng X; Gu J; Yao C; Liu S; Sun C; Pan F
    J Pept Sci; 2012 Jul; 18(7):476-86. PubMed ID: 22641352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
    Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
    Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide.
    Feni L; Parente S; Robert C; Gazzola S; Arosio D; Piarulli U; Neundorf I
    Bioconjug Chem; 2019 Jul; 30(7):2011-2022. PubMed ID: 31243977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design BH3 domain fusion protein as targeting pro-apoptotic self-assembling nanoparticles.
    Shuai Z; Zheng Y; Jiang J; Yu R; Zhang C
    Biomed Pharmacother; 2021 Sep; 141():111825. PubMed ID: 34153848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrin αvβ3 targeting activity study of different retro-inverso sequences of RGD and their potentiality in the designing of tumor targeting peptides.
    Liu Y; Mei L; Yu Q; Zhang Q; Gao H; Zhang Z; He Q
    Amino Acids; 2015 Dec; 47(12):2533-9. PubMed ID: 26173509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology.
    Dal Corso A; Pignataro L; Belvisi L; Gennari C
    Curr Top Med Chem; 2016; 16(3):314-29. PubMed ID: 26126915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells.
    Shan D; Li J; Cai P; Prasad P; Liu F; Rauth AM; Wu XY
    Drug Deliv Transl Res; 2015 Feb; 5(1):15-26. PubMed ID: 25787336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of RGD conjugated with Ketoprofen/Naproxen and radiolabeled with [
    Mohammadi R; Shokri B; Shamshirian D; Zarghi A; Shahhosseini S
    Daru; 2020 Jun; 28(1):87-96. PubMed ID: 31845157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid.
    Liang Y; Li S; Wang X; He B; He B; Dai W; Zhang H; Wang X; Wang Y; Zhou D; Zhang Q
    Theranostics; 2017; 7(13):3306-3318. PubMed ID: 28900511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel.
    Danhier F; Vroman B; Lecouturier N; Crokart N; Pourcelle V; Freichels H; Jérôme C; Marchand-Brynaert J; Feron O; Préat V
    J Control Release; 2009 Dec; 140(2):166-73. PubMed ID: 19699245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of Modified RGD-Based Peptides and Their in vitro Activity.
    Hamdan F; Bigdeli Z; Asghari SM; Sadremomtaz A; Balalaie S
    ChemMedChem; 2019 Jan; 14(2):282-288. PubMed ID: 30506622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature.
    Temming K; Schiffelers RM; Molema G; Kok RJ
    Drug Resist Updat; 2005 Dec; 8(6):381-402. PubMed ID: 16309948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conjugates of a novel 7-substituted camptothecin with RGD-peptides as α(v)β₃ integrin ligands: An approach to tumor-targeted therapy.
    Dal Pozzo A; Esposito E; Ni M; Muzi L; Pisano C; Bucci F; Vesci L; Castorina M; Penco S
    Bioconjug Chem; 2010 Nov; 21(11):1956-67. PubMed ID: 20949910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RGD mimetics γ-AApeptides and methods of use (US 20,140,004,039 A1): a patent evaluation.
    Wu H; Jiang J; Xu H; Li Q; Cai J
    Expert Opin Ther Pat; 2016; 26(1):131-7. PubMed ID: 26560186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.